BRVE Stock — Braveheart Bio Inc.: Cash, EV, Pipeline

Share price

$29.20

Market cap

$2,629.1M

Cash

$474.0M

Enterprise value

$2,155.1M

Balance sheet

Cash	$474.0M
Debt	$0.0M
Net cash	$474.0M
Enterprise value	$2,155.1M
Basic shares	7.5M shares
Fully diluted shares	150.6M shares
Fully diluted market cap	$4,397.0M
Cash per share	$63.20

Cash figures as of 2026-08-05. Database snapshot: 2026-09-21.

Price history

Loading BRVE daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Nov 12 - Dec 24	BHB-1893	Phase 3	Cardiomyopathy, Hypertrophic Obstructive	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

BHB-1893

Phase 3 · Active Modality: oral small molecule

Target cardiac myosin

Partnerships Hengrui: exclusive license agreement ($6.0M license milestone expense in Q1 2026)

Indications

Obstructive hypertrophic cardiomyopathy (oHCM) (Phase 3)
Non-obstructive hypertrophic cardiomyopathy (nHCM) (Phase 3)

Status note Lead product candidate; LIONHEART-HCM Phase 3 trial initiated in oHCM; global Phase 3 development planned in oHCM and nHCM. IPO completed Aug 7, 2026 ($404.5M net proceeds).

Per-asset detail extracted from the 10-Q filed 2026-09-08. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	BHB-1893
Lead indication	Cardiomyopathy, Hypertrophic Obstructive
Lead phase	Phase 3
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07755904	Phase 3	Not yet recruiting	Sponsor	BRVE	—	Cardiomyopathy, Hypertrophic Obstructive	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Braveheart Bio, Inc. on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

BRVE — Braveheart Bio Inc.